Verified employee & interview reviews

Natco Pharma Reviews

Hyderabad, Telangana

4.7/ 5

3 reviews

NATCO Pharma Limited is a prominent research and development-driven Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Established in 1981 by V. C. Nannapaneni, the company has built a specialized market position over more than four decades, focusing on complex generic pharmaceuticals, niche molecules, and active pharmaceutical ingredients (APIs). NATCO operates as a vertically integrated player with an extensive global footprint, exporting its products to over 50 countries and maintaining a significant commercial presence in high-entry-barrier markets, particularly the United States, Canada, Europe, and emerging economies. The company's core operations are divided across several major business segments: pharmaceutical formulations (both domestic and international), active pharmaceutical ingredients, and its rapidly expanding Crop Health Sciences division. Within its pharmaceutical portfolio, NATCO is highly recognized as a leader in the oncology segment, offering a diverse range of branded targeted therapies for various cancers (including blood, liver, kidney, lung, brain, breast, and ovary) at affordable prices in the domestic Indian market. In addition to oncology, its specialty therapeutics divisions address critical therapeutic areas such as cardiology, diabetology, gastroenterology, hepatology, neurology, and ortho-rheumatology. NATCO operates nine world-class manufacturing facilities approved by major global regulatory authorities, including the US FDA, Brazil ANVISA, Health Canada, and the European Directorate for the Quality of Medicines (EDQM). Its production capabilities are heavily supported by strong in-house research and development capabilities, holding dozens of active US Drug Master Files (DMFs) and a pipeline of numerous international patents. The company strategic focus remains on filing high-value, limited-competition Abbreviated New Drug Applications (ANDAs), such as its prominent profit-sharing arrangements in the US market. Beyond healthcare, NATCO has strategically diversified into the agrochemical sector through its Crop Health Sciences division. Utilizing its expertise in organic chemistry and advanced formulations, the division manufactures selective active ingredients, pest management solutions, and crop protection formulations, such as Chlorantraniliprole (CTPR) and innovative pheromone-based mating disruption products. Financially, NATCO Pharma Limited is publicly traded on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker NATCOPHARM. The company has shown consistent financial strength, reporting a consolidated revenue of ₹4,784 crore for the fiscal year 2025. This growth trajectory continued into fiscal year 2026, driven by strong international generic formulations and corporate expansion, including the strategic acquisition of a 35.75% stake in South African pharma entity Adcock Ingram. Led by Founder, Chairman, and Managing Director V. C. Nannapaneni alongside Vice Chairman and CEO Rajeev Nannapaneni, NATCO employs over 5,000 people globally while emphasizing strong corporate governance, environmental responsibility, and green chemistry innovation.